Skip to main content

Table 5 Impacts of anti-IL5/IL5R and anti-IgE therapy on upper respiratory tract findings and need for treatment in asthma patients receiving biologicals. The parameters were adjusted to match a 12-month period of biological therapy. Patients with discontinued biological therapy were included in the analyses

From: A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences

  Anti-IL5/IL5R (Reslizumab, Mepolizumab, Benralizumab) N = 38   Anti-IgE (Omalizumab) N = 17  
Baseline Change P Baseline Change P
Courses of OCS (number/year) a 1.24 (0–8. SD 2.03) −0.79 (−8–2. SD 2.14) 0.031 0.82 (0–3. SD 1.04) −0.59 (−3–1. SD 1.03) 0.037
Courses of antibiotics (number/year) 0.94 (0–5. SD 1.26) 0.12 (−4–5. SD 1.99) 0.718 1.12 (0–4. SD 1.23) −0.22 (− 3–7. SD 2.09) 0.674
Polypectomy (number) 1.37 (0–20. SD  3.29) −1.24 (−20–1. SD 3.30) 0.028 1.59 (0–20. SD 4.67) −1.41 (− 20–1. SD 4.69) 0.246
Ethmoidectomy (number) 0.76 (0–4. SD 0.87) −0.71 (− 4–1. SD 0.94) 5.10 e− 05 0.29 (0–1. SD 0.46) −0.12 (− 1–2. SD 0.68) 0.496
FESS (number) b 1.03 (0–4. SD 0.87) − 0.95 (− 3–1. SD 0.89) 1.34 e− 07 1.12 (0–4. SD 1.13) −0.82 (− 4–1. SD 1.25) 0.018
Polyps in nasal inspection (number, (%)) 22 (58) −9 0.038 7 (41) −1 0.724
Mucous oedema in nasal inspection (number, (%)) 19 (50) −12 0.004 7 (41) + 4 0.169
  1. aOCS = per oral corticosteroid
  2. bFESS = Functional endoscopic sinus surgery